Literature DB >> 14990356

Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms.

Li-Man Hung1, Ming-Jai Su, Jan-Kan Chen.   

Abstract

We previously showed that resveratrol (3,4',5-trihydroxystilbene) stimulates NO production and is cardioprotective in rat heart subjected to ischemia-reperfusion (I/R rat heart). We now show that in I/R rat heart, inducible nitric oxide synthase (iNOS) expression is markedly induced, while expression of endothelial nitric oxide synthase (eNOS) and nueronal nitric oxide synthase (nNOS) is unchanged. In animals preconditioned with resveratrol (0.5 to 1 mg/kg body wt), I/R-induced iNOS induction is abrogated; however, expression of eNOS and nNOS is greatly upregulated. The protective effects of resveratrol on I/R rat heart include reduced rhythm disturbances, reduced cardiac infarct size, and decreased plasma levels of lactate dehydrogenase (LDH) and creatine kinase (CK). Among these, the reductions in LDH/CK levels and infarct size are NO-dependent as the coadministration of N(omega)-nitro-L-arginine methyl ester (L-NAME, 1 mg/kg body wt) with resveratrol abolishes the resveratrol effect. In contrast, the reductions in the severity of ventricular arrhythmia and mortality rate are not affected by L-NAME coadministration, suggesting that a NO-independent mechanism is involved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990356     DOI: 10.1016/j.freeradbiomed.2003.12.016

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  47 in total

Review 1.  Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy.

Authors:  Nagalingam R Sundaresan; Vinodkumar B Pillai; Mahesh P Gupta
Journal:  J Mol Cell Cardiol       Date:  2011-01-27       Impact factor: 5.000

2.  Inhibition of cardiac voltage-gated sodium channels by grape polyphenols.

Authors:  C H R Wallace; I Baczkó; L Jones; M Fercho; P E Light
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

Review 3.  Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies.

Authors:  Belma Turan; Erkan Tuncay; Guy Vassort
Journal:  J Bioenerg Biomembr       Date:  2012-04       Impact factor: 2.945

Review 4.  Translating cell survival and cell longevity into treatment strategies with SIRT1.

Authors:  K Maiese; Z Z Chong; Yan Chen Shang; S Wang
Journal:  Rom J Morphol Embryol       Date:  2011       Impact factor: 1.033

Review 5.  Targeting cardiovascular disease with novel SIRT1 pathways.

Authors:  Zhao Zhong Chong; Shaohui Wang; Yan Chen Shang; Kenneth Maiese
Journal:  Future Cardiol       Date:  2012-01

6.  Resveratrol and exercise.

Authors:  Saltuk Bugra Baltaci; Rasim Mogulkoc; Abdulkerim Kasim Baltaci
Journal:  Biomed Rep       Date:  2016-10-11

Review 7.  Resveratrol: a medical drug for acute pancreatitis.

Authors:  Zhen-Hua Ma; Qing-Yong Ma
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

8.  Luteolinidin Protects the Postischemic Heart through CD38 Inhibition with Preservation of NAD(P)(H).

Authors:  James Boslett; Craig Hemann; Yong Juan Zhao; Hon-Cheung Lee; Jay L Zweier
Journal:  J Pharmacol Exp Ther       Date:  2017-01-20       Impact factor: 4.030

Review 9.  Sirtuins and NAD+ in the Development and Treatment of Metabolic and Cardiovascular Diseases.

Authors:  Alice E Kane; David A Sinclair
Journal:  Circ Res       Date:  2018-09-14       Impact factor: 17.367

Review 10.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.